Ignite Creation Date:
2025-12-24 @ 11:45 PM
Ignite Modification Date:
2025-12-25 @ 9:38 PM
Study NCT ID:
NCT05512351
Status:
RECRUITING
Last Update Posted:
2022-09-27
First Post:
2022-08-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
Sponsor:
Henan Provincial People's Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-12-23
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12
Completion Date Type:
ESTIMATED
First Submit Date:
2022-08-21
First Submit QC Date:
None
Study First Post Date:
2022-08-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-09-25
Last Update Post Date:
2022-09-27
Last Update Post Date Type:
ACTUAL